The process: starting wide, then narrowing
The work began at a macro level. Publicly available data only. No internal metrics. No proprietary performance numbers.
The scan covered early- to late-stage biotech ventures with validated funding, active pipelines, and visible digital footprints. The goal wasn’t selection. It was orientation.
From there, the process narrowed:
- Macro digital signals: long-term shifts in search behaviour across therapy areas
- Category-level momentum: comparing emerging versus established treatment spaces
- Company-level visibility: brand search volume, growth trends, and digital engagement
- Light digital due diligence: websites, SEO, organic reach, AI visibility, and social presence
This approach creates context early. Not certainty.
What the digital market signals suggest
Some therapy areas are seeing faster growth in public and professional attention than others.
Emerging and innovation-heavy domains show rising search activity year over year.
More established disease areas tend to show steadier, flatter interest.
This doesn’t imply commercial outcomes. But it does suggest where curiosity, awareness, and conversation are forming faster.
Another pattern stands out.
Public-facing topics often attract more digital attention than highly specialised scientific niches. That gap matters when scaling awareness, partnerships, or future recruitment.
Digital interest doesn’t equal clinical success. But it can influence visibility, narrative, and perceived relevance.
Brand visibility is uneven even among peers
When comparing companies operating in similar scientific spaces, digital presence varies widely.
Some show: a) Rising brand searches, b) Consistent visibility over time, c) Spikes linked to funding, publications, or media moments
Others remain flat. Or quietly decline.
Importantly, high search volume and positive growth don’t always move together. A company can be widely searched but losing momentum. Another can be small but gaining attention.
Direction matters as much as size.
The quiet gap: social and engagement
One of the most consistent findings is what’s missing. Across the board, social media performance lags behind other digital indicators.
Websites and SEO often perform reasonably well. Organic discovery is present. But ongoing engagement is thin.
This isn’t surprising.
Many science-led teams prioritise R&D over communication. The opportunity lies in alignment, not amplification. A stronger digital presence doesn’t require louder marketing. It requires clarity, consistency, and relevance.
Why this matters for investors and acquirers
Digital due diligence isn’t about prediction. It’s about perspective.
It helps answer early questions like:
Where is attention already forming?
If digital signals help you narrow a broad list of targets down to a smaller group worth full diligence, everyone can do the math on what that means for their own cost structure and capital allocation.
Which narratives are gaining traction without paid push?
A brand growing from 400 searches at +75% annually becomes 1,225 searches in two years, meaning digital visibility can triple before valuation fully adjusts.
Which teams may benefit most from digital activation post-investment?
In a scenario where the website traffic increases by +40% and conversion improves from 2% to 3%, leads rise from 10 to 21 per month, more than doubling potential partnership flow.
Used early, it can save time. Used later, it can add context.
If digital filtering eliminates 30 of 100 targets and each review takes 20 partner-hours, that saves 600 hours (everyone should do the math on how much cost saving is this) which can be redirected to higher-quality deals.
Most importantly, it complements financial, legal, and scientific reviews rather than competing with them.
Closing thought
Digital signals don’t decide outcomes. But they do leave clues.
In sectors where timelines are long and visibility matters, those clues can shape how opportunities are prioritised, supported, and scaled.
The smartest move isn’t to overinterpret them. It’s to include them.
